

Accepted Article

Title: Synthesis of Nitrogen-Containing Heterocycles and Cyclopentenone Derivatives via Phosphine-Catalyzed Michael Addition/Intramolecular Wittig Reaction

Authors: Nidal Saleh, Florent Blanchard, and Arnaud Voituriez

This manuscript has been accepted after peer review and appears as an Accepted Article online prior to editing, proofing, and formal publication of the final Version of Record (VoR). This work is currently citable by using the Digital Object Identifier (DOI) given below. The VoR will be published online in Early View as soon as possible and may be different to this Accepted Article as a result of editing. Readers should obtain the VoR from the journal website shown below when it is published to ensure accuracy of information. The authors are responsible for the content of this Accepted Article.

To be cited as: Adv. Synth. Catal. 10.1002/adsc.201700313

Link to VoR: http://dx.doi.org/10.1002/adsc.201700313

10.1002/adsc.201700313

FULL PAPER

DOI: 10.1002/adsc.201((will be filled in by the editorial staff))

Synthesis of Nitrogen-Containing Heterocycles and Cyclopentenone Derivatives via Phosphine-Catalyzed Michael Addition/Intramolecular Wittig Reaction

Nidal Saleh, Florent Blanchard and Arnaud Voituriez*

Institut de Chimie des Substances Naturelles, CNRS UPR 2301, Université Paris-Sud, Université Paris-Saclay, 1 av. de la Terrasse, 91198 Gif-sur-Yvette, France. E-mail: <u>arnaud.voituriez@cnrs.fr</u>; Fax : +33 (0)1 69 07 72 47.

Received: ((will be filled in by the editorial staff))

Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/adsc.201########.

Abstract. The phosphine-catalyzed Michael addition/intramolecular Wittig reaction between dialkyl acetylenedicarboxylate and amino-carbaldehyde or amino-ester derivatives has been developped. This reaction can be rendered catalytic in phosphine by the in situ chemoselective reduction of the phosphine oxide with silane. This methodology enables rapid access to a variety of nitrogen-containing heterocycles, which are present in numerous natural products and/or bioactive compounds.

Either classical heating or microwave conditions give access to the desired products in good yields (15 examples, 60-99% yields). This catalytic methodology is further applicable to the synthesis of enantioenriched 1*H*-pyrrole derivatives, with the use of chiral phosphines. Finally, we successfully extended the reaction to the synthesis of polysubstituted cyclopentenone, starting from butane-2,3-dione as substrate.

Keywords: Phosphine; Organocatalysis; In situ reduction; Cyclization; Wittig reaction

Introduction

phosphine-promoted Stoichiometric processes, such as the Wittig, Staudinger, and Mitsunobu reactions are widely used in organic synthesis.^[1] In addition to these well-known transformations, some interesting phosphine-mediated annulation reactions have been recently described, giving access to a wide range of heterocycles.^[2] Despite their usefulness, these reactions possess a major drawback, namely the concomitant formation of a stoichiometric quantity of phosphine oxide, which often complicates the purification of large-scale processes and globally decreases the atom economy.^[3] With the aim of developing a more environmentally friendly chemistry, a substoichiometric amount of phosphine should be ideally employed. To reach this goal, different strategies have been undertaken, such as the activation of the phosphine oxide with isocyanates^[4] or oxalyl chloride,^[5] and the in situ chemoselective reduction of the phosphine oxide formed during the reaction. The latter strategy is the most popular,^[6] and consequently many reactions were already rendered catalytic in phosphine (catalytic loading of 5-20 mol%) upon using a stoichiometric quantity of a reducing agent, such as silane.^[7]

Relying on this strategy, we have developed the first catalytic cyclization reactions between the socalled Huisgen zwitterion and α -ketoester derivatives.^[8] Recently, we also reported the first phosphine-catalyzed sequential addition/intramolecular Wittig reaction between dialkylacetylenedicarboxylate (DAAD) and indole-2-carboxaldehyde derivatives, for the synthesis of highly functionalized 9*H*-pyrrolo[1,2-*a*]indoles (Scheme 1a).^[9]



Scheme 1. Phosphine-catalyzed synthesis of nitrogencontaining heterocycles and cyclopentenone derivatives.

Herein, we propose to fully explore the scope of the catalytic addition/intramolecular Wittig reaction between DAAD, amino-carbaldehyde and aminoester derivatives, and therefore expand our methodology towards an easy access to plenty of *N*-containing condensed heterocycles (Scheme 1b).

Although few of these structures have already been obtained by using stoichiometric amounts of phosphine,^[10] were other products directly synthesized with this catalytic methodology. The process proved to be very efficient for developing quickly a library of various heterocyclic scaffolds well known for their biological properties and their presence in many drugs.^[11] For example, as shown in Figure 1, mitomycin A (I) based on a pyrrolo[1,2a]indole core is an effective anti-tumor agent.^[12] Licofelone (II) based on a pyrrolizine core is an analgesic, an anti-inflammatory agent, and considered as a treatment for osteoarthritis.^[13] Vinpocetine (III), based on an indole-naphthyridine backbone, enhances the cerebral blood-flow, has neuroprotective effects and was used as a drug for the treatment of cerebrovascular disorders.^[14]



Figure 1. Some natural and bioactive products containing the targeted heterocycles and carbocycles.

In addition to N-containing heterocycles, the "catalytic addition/intramolecular Wittig reaction" methodology can be interestingly extended towards the synthesis of 4-oxocyclopent-2-ene-1,2dicarboxylate derivatives. This skeleton was found in alprostadi1^[15] several drugs such as (IV)(Prostaglandin E1 (PGE1)), used in the continuous treatment of erectile dysfunction,^[16] as well as in natural products such as Jasmone (V) which is a volatile portion of the oil from jasmine flowers. Trilobolide (VI), a bioactive compound possessing anticancer activities, could be synthesized also from this key builduing block.^[17] In addition, our methodology gives access to products containing stereogenic centers, thus we were interested to assess the possibility of developing the first catalytic and asymmetric version of such tandem addition/intramolecular Wittig reaction. To further validate the synthetic flexibility of this methodology, we envisioned applying it to a wide range of substrates, and the main results of these studies are summarized hereafter.

Results and Discussion

I) Phosphine-catalyzed synthesis of diverse nitrogen-containing condensed heterocycles.

The major challenges to circumvent during the development of phosphine-catalyzed reactions are: i) the choice of an appropriate reducing agent to chemoselectively reduce in situ the phosphine oxide without altering the starting materials, intermediates, and/or products; ii) the phosphine oxide should be easily reduced and iii) the trivalent phosphine should exhibit a good nucleophilicity. It is well known nowadays that the 5-membered ring cyclic phosphines possess these features and that [R₃SiH/Brønsted acid] as a reducing system can tolerate a wide range of functional groups.^[6a,7c,8,9] Moreover, the mixture phenylsilane/bis(4-nitrophenyl)phosphate is known to efficiently five-membered ring reduce cyclic phosphine oxide at 60°C in toluene. Indeed, the 4methyl-1-phenyl-2,3-dihydrophosphole **P1** catalyst proved to be very efficient in the synthesis of pyrroloindole and pyrrolizine derivatives (scheme 1a).^[9]

So, we decided to fully explore the substrate scope of this reaction, by using different aminocarbaldehydes (Table 1). Using the catalytic system {P1 (5 mol %) as pre-catalyst, 5 mol % of bis(4nitrophenyl)phosphate, phenylsilane (1 equiv.), for 16 hours at $60^{\circ}C$, a wide range of umpolung addition/Wittig reactions was developed, giving access to a variety of N-containing condensed heterocycles. First of all, the diethyl 7-bromo-9Hpyrrolo[1,2-a]indole-2,3-dicarboxylate product 3a was synthesized in 92% yield (Table 1, entry 1).^[9] The structural assignment of this molecule was ascertained by single crystal X-ray analysis (Figure 2a), that verified the double bond migration after the intramolecular Wittig reaction (see the mechanism Scheme 2). Similarly, we were able to generalize the synthesis of dialkyl 3H-pyrrolizine-5,6-dicarboxylate derivatives **3ba-3bc** from **1b**. Starting from commercially available pyrrole-2-carbaldehyde and diethyl, dimethyl, and di-*tert*-butyl acetylene dicarboxylate **2a-c**, the corresponding 3*H*-pyrrolizines **3ba-3bc** were obtained in 83-90% yields (entries 2-4). It is worth noting that the structure of this bicyclic backbone was confirmed by X-ray diffraction study on crystals of 3ba (Figure 2b). The more stable 3Hpyrrolizine isomer was isolated, contrary to the chemical structure of 1H-pyrrolizine, reported by Yavari et al.^[10c] By ¹H and ¹³C NMR analysis, we have the characteristic signals of the -NCH₂- moiety of **3ba** [δ 4.66 (C<u>H</u>₂); 55.4 (<u>C</u>H₂)] [δ 4.76 (C<u>H</u>₂); 55.1

 $(\underline{CH}_2)]^{[10c]}$ and **3bc** [δ 4.70 (C<u>H</u>₂); 55.1 (<u>C</u>H₂)] [δ 4.69 (C<u>H</u>₂); 55.1 (<u>C</u>H₂)].^[10c]

Diethyl 4H-pyrrolo[3,2,1-*ij*]quinoline-4,5dicarboxylate derivatives **3c,d** (entries 5,6) were obtained in 96% and 94% yield, respectively, from commercially available 1H-indole-7-carbaldehydes. Once more, the structure of **3c** was confirmed by Xray diffraction studies (Figure 2c).

 Table 1. Scope of different classes of N-containing condensed heterocycles.



^{a)} Isolated yields. ^{b)} Classical heating, using an oil bath, 60°C, 16h. ^{c)} Microwave reactor, 100°C, 2h. ^{d)} Results from ref. [9].

Moreover, a highly complex *N*-containing heterocycle **3e** could be obtained in 86% yield, starting from the 1-formyl-9*H*-pyrido[3,4-b]indole-3-carboxylate substrate **1e** (entry 7). In this case, some

solubility problems of the starting material **1e** occurred, forcing the use of THF as a co-solvent to ensure a decent yield. Similarly, 1-Boc-2,3-diethyl quinoline-1,2,3(2*H*)-dicarboxylate **3f** was obtained in 73% yield (entry 8) and the tricyclic diethyl 1-tosyl-1,2-dihydrobenzo[4,5]thieno[3,2-*b*]pyridine-2,3-dicarboxylate **3g** in 60% yield (entry 9).



Figure 2. ORTEP-3 plot of a) **3a** (CCDC 1489491); b) **3ba** (CCDC 1489494); c) **3c** (CCDC 1489495) and d) **5d** (CCDC 1489493). Ellipsoids are drawn at the 50% probability level and H atoms are shown as spheres of arbitrary radius.

Inspired by Werner and coworkers, who developed the first microwave-assisted catalytic Wittig reaction (CWR),^[18] we decided to switch from classical heating conditions (oil bath, 60°C, 16h) to microwave heating (100°C, 2h). Keeping the reaction conditions developed previously, we studied the microwaveassisted performance of the addition/intramolecular CWR on the same substrates. Interestingly, all the reactions in table 1 (except for entry 7) were finished just after 2 hours while heating at 100°C, without decreasing the yields. On the contrary, the yields were even enhanced with some substrates (entries 3, 5, 6). Increasing the reaction temperature did not have any influences in the reaction time or in the reaction yields. The only disappointing result came from the substrate 1e (entry 7), due to the low solubility of pyrido[3,4-b]indole-aldehyde substrate in toluene.

This catalytic system showed to be very efficient and allows an easy access to a wide library of different *N*-containing condensed heterocycles with very high yields and faster reaction rates.

II) Phosphine-catalyzed synthesis of chiral tetrahydropyridine and 2,5-dihydro-1*H*-pyrrole derivatives.

Interestingly, this methodology can be also extended to acyclic amino-aldehyde and amino-ester substrates, as shown in Table 2, to prepare the corresponding tetrahydropyridine and 2,5-dihydro-

Advanced Synthesis & Catalysis

1*H*-pyrrole heterocycles.

 Table 2. Synthesis of diverse N-containing heterocycles.



^{a)} Isolated yields. ^{b)} Classical heating, using an oil bath, 120°C, 16h. ^{c)} Microwave reactor, 120°C, 2h. ^{d)} Classical heating, using an oil bath, 60°C, 16h. ^{e)} Microwave reactor, 100°C, 2h.

Diethyl tetrahydro-pyridine dicarboxylate derivatives with tosyl (**5a**) and Cbz (**5b**) protecting groups were obtained in 79% and 90% yields respectively, starting from *N*-protected 3-aminopropanal substrates (entries 1-2). Diethyl-4-ethoxy-2,5-dihydro-1*H*-pyrrole dicarboxylate with tosyl (**5c**) and Cbz (**5d**) as protecting groups were obtained in 80% and 92% yields, respectively, from protected commercially available amino-esters and

DAAD (entries 3-4). In the latter case, the intramolecular Wittig reaction with ester group requires to increase the reaction temperature to 120°C, to obtain a total conversion.

We can note that **5d** was obtained as a mixture of two rotamers, due to the Cbz group. The structural assignment of this molecule was ascertained by single crystal X-ray analysis (Figure 2d). Finally, the higher reactivities of Cbz-protected substrates, compared to the tosyl-protected one can be explained by the lower nucleophilicity of the nitrogen atom in the case of NTs, compared to the NCbz substrate.

Diastereoselective reaction could be also performed, starting from enantiopure *D*-phenylalanine ethyl ester and DAAD (entry 5). A mixture of 2 diastereoisomers **5e** and **5e'** in 2:1 ratio was obtained, in 82% overall yield. With the *L*-proline ethyl ester substrate, only one diastereoisomer **5f** was synthesized in 83% yield (entry 6).

Moreover, the microwave-assisted reaction of the umpolung addition/CWR with acyclic aminoaldehydes worked properly at 100°C for 2 hours, to furnish **5a** and **5b** in 81-92% yield (entries 1-2). Concerning the use of amino-esters, the reaction temperature was at 120°C for 2h, giving access to the dihydropyrroles **5c-5f** in 82-97% isolated yields (entries 3-6). The microwave heating condition has not modified and/or altered the diastereomeric ratio in the case of products **5e** and **5f**.

As previously reported and according to the accepted mechanism, [10a-b] the trivalent phosphine adds to the DAAD to form the zwitterionic species A (Scheme 2).^[19] The latter is subsequently protonated by the NH proton of the substrate, to give the corresponding vinylphosphonium salt **B**. The addition of the conjugate base of the substrate to **B** furnishes the ylide C, which undergoes an intramolecular Wittig reaction to form **D**. In some cases, migration of the double bonds formed the product E. Finally, the phosphine oxide generated by the Wittig olefination is reduced in situ by silane to the corresponding trivalent phosphine, to realize the $P^{V}=O/P^{III}$ redox cycling. Both trivalent phosphine or the corresponding phosphine oxide can be used indifferently at the beginning of the reaction. In the latter case the first step is the reduction of the P=O bond.



Scheme 2. Mechanism proposal for the phosphinecatalyzed addition/intramolecular CWR.

This mechanism was supported by the isolation of the stable phosphorus ylide 6 (Scheme 3). The reaction of ethyl 2-(benzyloxycarbonylamino)acetate 4d and DAAD 2a at room temperature, in presence of a stoichiometric quantity of triphenylphosphine, afforded the compound 6 in 80% yield. The 1 H and ³¹P NMR spectra showed two series of signals ascribed to the respective two rotamers (see the Supporting Information).^[20] Afterwards, the isolated phosphorus ylide 6 undergoes an intramolecular Wittig reaction with the carbonyl of the ester group, upon refluxing in toluene. The corresponding product 5d and triphenyl phosphine oxide are formed quantitatively. The reaction can be followed by ³¹P NMR: we observed the disappearance of the two peaks of **6** (δ = 26 and 27 ppm) and the formation of Ph₃P=O (δ = 30 ppm) (See Supporting Information).



Scheme 3. Synthesis of the phosphorus ylide **6** and subsequent intramolecular Wittig reaction.

III) Catalytic and asymmetric umpolung addition/ intramolecular Wittig reaction.

In the following, one of our biggest interests, as well as the most challenging goal, was to develop a catalytic and asymmetric reaction, mediated by a chiral phosphine. At first, we screened several commercially available chiral phosphines to prove the concept of a catalytic and asymmetric tandem reaction. To the best of our knowledge, there is only one precedent in the literature of a catalytic and asymmetric Wittig reaction, with the use of (S,S)-Me-DuPhos (10 mol%) as chiral catalyst, in presence of HSi(OMe)₃. The conversion was less than 10%, but the enantiomeric excess was about 90% ee.[21] Contrary to this seminal example, where the enantioselective step occurred during the Wittig reaction, via a desymmetrisation reaction of a prochiral diketone substrate with the phosphorus ylide, in our case the enantioselective step is the addition of nitrogen anion to the vinylphosphonium the intermediate **B**, to furnish the ylide **C** (Scheme 2).^[22] The best results are reported in Table 3.

Table 3. Asymmetric and catalytic process.



^{a)} Isolated yields. ^{b)} Determined by HPLC on a chiral stationary phase.

(1R,1'R,2S,2'S)-DuanPhos **P2** and 2-{2-[(2R,5R)-2,5-diethyl-1-phospholano]phenyl}1,3-dioxolane **P3** (Table 3, entries 1 and 2) gave the best enantioselectivities with 70% and 81% ee, but in relatively low yields, in presence nevertheless of respectively 75 mol% and 150 mol% of phosphine (50% and 30% yields). Unfortunately, incorporation of 5-20 mol% of these chiral phosphines in the reaction mixture resulted in the formation of traces of the desired product **5d** after refluxing in toluene for 24 hours, and thereby does not allow the development of the catalytic and asymmetric reaction. That proved

the difficulties to find a chiral phosphine which is easily reducible, but also nucleophilic enough to catalyse the reaction. In general, cyclic phosphines, such as phenylphospholane oxide, are more easily reducible by silanes than acyclic phosphines. And this particularity of cyclic phosphine is especially true for the five-membered rings, such as catalyst P1-5. On the other hand, the steric hindrance around the phosphorus atom could explain the lower reactivity of P2 and P3. Fortunately, the use of 5 mol% of (1S,4S,5R)-5-phenyl-2-tosyl-2-aza-5 phosphabicyclo [2.2.1]heptane P4 (Kwon bicyclic phosphine catalyst)^[23] gave the desired product in 67% yield, but with a moderate enantiomeric excess (17% ee, entry 3). Finally, the new chiral catalyst **P5**, a phosphindole-1-oxide bearing a chiral menthyl group, showed the best catalytic activity (94% yield, entry 4) and significant enantioselectivities (30% ee), with only a catalyst loading of 5 mol%. These interesting preliminary results showed the development of a catalytic and enantioselective tandem addition/CWR, previously known as racemic and stoichiometric in phosphine.

IV) Synthesis of 4-oxocyclopent-2-ene-1,2dicarboxylate derivatives

In the continuity of this work concerning the catalytic development of new reactions, we wondered whether it was possible to spread the reactivity of DAAD to other substrates, to obtain carbocycles. In 2004, Yavari et al. firstly reported the synthesis of di-3-methyl-4-oxocyclopent-2-ene-1,2*tert*-butvl dicarboxylate 8a (Scheme 4a) using stoichiometric amount of PPh₃ as a promoter for the reaction between di-tert-butyl acetylene dicarboxylate 2c and butane-2,3-dione 7.^[24] In the literature, 8a proved to be an essential building block in the synthesis of natural products of trilobolide (see structure (VI) in Figure 1).^[17] However, on bigger scale, Férézou et al. proved to have some difficulties to reproduce the synthesis of 8a, following the Yavari's procedure. On 20g scale reaction, 1 equiv. of PPh₃ was used with 20 equiv. of 7 to obtain 8a in 63% yield, as summarized in scheme 4a. Hence, large amounts of wastes were produced, and therefore developing a catalytic version of this reaction could be very interesting (Scheme 4b).





Scheme 4. Synthesis of cyclopentenone derivatives.

Initially, we examined the outcome of the reaction of acetylene dicarboxylate 2c (1-3 equiv.) with butane-2,3-dione 7, in the presence of sub-stoichiometric amounts of phosphine and silane. The reaction was conducted with 20 mol% of 4-methyl-1-phenyl-2,3dihydrophosphole 1-oxide, 20 mol % of (p-NO₂PhO)₂PO₂H and 2.8 equiv. of Me(EtO)₂SiH for 16 hours at 70°C in toluene. Only traces of 8a were observed with 1 equiv. of substrate 7, independently of the concentration used (table 2, entries 1-2). To our delight, 8a was formed in 33% yield, with the use of 2 equiv. of substrate 7 (entry 3). The use of other solvents (dioxane, dichloroethane; entries 4-5) did not improve the reaction rate. Surprisingly, the yield was increased to 48% while adding 20 mol% of DIPEA (entry 6), but the addition of 100 mol% of DIPEA had a negative effect on the catalytic activity (18% yield, entry 7). Enhanced yields were obtained at 90°C and 110°C (50% and 66% yields, respectively, entries 8-9). Traces of **8a** were produced by using PPh_3 as catalyst, and 54% yield was obtained with the Pphenyl-dibenzophosphole **P6** (entries 10-11). Interestingly, best reaction conditions were reached, as reported in entry 12, while using 3 equiv. of biacetyl 7. The desired product 8a was obtained in 83% NMR yield (77% isolated yield). Decreasing the amounts of Me(EtO)₂SiH to two equivalents had a negative impact on the reaction rate (50% yield, entry 13).



			50			
	Bu Me O	Ph	or P6 (20 mol %) Me		CO₂ <i>t</i> Bu	
		(ArO) ₂ PO ₂ DIPEA	₂H (20 mol %) (x mol %) 0⊄	$\overline{}$	∽CO₂tBu	
2c (1 equ	7 uiv.) (n equiv.)	Me(OEt) ₂ S solver	iH (2.8 equiv.) ht, T, 18 h	8a		
Entr	7 (n equiv.)	DIPEA (x	solvent, [c]	T (°C)	Yield (%) ^{a)}	0
		mol%)	T 1 [0.1]			
1	I	-	Toluene, [0.1]	/0	5	
2	1	-	Toluene, [0.2]	70	5	
3	2	-	Toluene, [0.2]	70	33	
4	2	-	Dioxane, [0.2]	70	20	
5	2	-	DCE, [0.2]	70	15	
6	2	20	Toluene, [0.2]	70	48	
7	2	100	Toluene, [0.2]	70	18	
8	2	20	Toluene, [0.2]	90	50	
9	2	20	Toluene, [0.2]	110	66	
10 ^{b)}	2	20	Toluene, [0.2]	110	<5	
11 ^{c)}	2	20	Toluene, [0.2]	110	54	
12	3	20	Toluene, [0.2]	110	83 (77) ^{d)}	
13 ^{e)}	3	20	Toluene, [0.2]	110	50	
14 ^{f)}	3	20	Toluene, [0.2]	110	39	_

^{a)} NMR yields were determined using trimethoxybenzene as an internal standard. ^{b)} Use of PPh₃ instead of phospholene catalyst. ^{c)} Use of **P6** instead of phospholene catalyst. ^{d)} Isolated yield. ^{e)} Me(OEt)₂SiH (2.0 equiv. instead of 2.8 equiv.). ^{f)} Without (ArO)₂PO₂H. DIPEA = N,N-diisopropylethylamine; DCE = 1,2-dichloroethane.



Finally, the importance of bis(4-nitrophenyl) hydrogen phosphate in the reaction mixture was proved (only 39% yield without (ArO)₂PO₂H, entry 14). This result demonstrated the pivotal role of the phosphate in the P(V)/P(III) redox catalytic cycle. Under these reaction conditions, no better isolated yields were obtained with PhSiH₃ or Ph₂SiH₂.

The practicability of our catalytic protocol was further demonstrated by a 2.2-mmol-scale synthesis of product **8a**. The desired product was obtained in 77% isolated yield (0.50 g). This scalability proves the robustness of our catalytic methodology and applications in the synthesis of key building blocks can be now envisaged.

This methodolgy was also extended to the synthesis of di-*tert*-butyl 4-oxo-3-phenylcyclopent-2-ene-1,2-dicarboxylate **8b** in 51% (Scheme 5). Moreover, **8a** and **8b** were obtained in 65% and 53% yields, respectively, while performing these reactions in microwave at 120° C for 2 hours.



Scheme 5. Application of the catalytic methodology to the synthesis of substrate **8b**.

Concerning the reaction mechanism (Scheme 6), nucleophilic addition of the phosphine to DAAD 2c produces the zwitterionic species **F**, which reacts as a base to deprotonate the diketone substrate 7 or 9. The enol intermediate subsequently adds on vinylphosphonium G to form the oxaphosphetane H. which produced the desired product 8a,b and phosphine oxide as a concomitant by-product. In situ reduction of this phosphine oxide with silane such as phenylsilane allowed the regeneration of the active catalyst and close the catalytic cycle. During the phosphine oxide reduction, the phosphate proved to be necessary to facilitate this process (as showed in Table 4, entry 14). Thus, it is postulated that the in situ formed phosphoric silyl ester I (Scheme 6) acts as a bifunctional catalyst.^[25] Both the oxygen atom of the phosphine oxide and the silane are activated by the Lewis acid/Lewis base properties of this organocatalyst. In this process the tertiary amine base

DIPEA seems to have an important role by avoiding the protonation of the enol intermediate.



Scheme 6. Proposed mechanism for the synthesis of products 8a,b.

Conclusion

The phosphine-catalyzed Michael addition/Wittig reactions tolerate a wide range of substrates, giving access to the corresponding heterocycles and cyclopentenone derivatives in good yields, either using classical heating or microwave conditions (17 examples, 60-99% yields). We are confident that our methodology could find applications in organic chemistry, particularly in medicinal chemistry, where people are interested in obtaining a large number of molecules, structurally varied, in minimum time. Finally, the use of a catalytic quantity of phosphine is even more relevant in the case of the use of a chiral phosphine. Given the prohibitive cost of these chiral catalysts, it is inconceivable to use in these reactions a stoichiometric quantity. The use of our method allows now to use of small quantity of catalyst, to obtain easily an enantioenriched product. Even if the results described here are preliminary, they are the first significant results in the domain. In the future, our work is going to concentrate on the discovery of new phosphine-catalyzed reactions, and in the development of asymmetric reactions. The synthesis of new chiral phosphines, especially designed to improve the current results will be reported in due course.

Experimental Section

I. General information:

All non-aqueous reactions were run under a positive pressure of argon, by using standard techniques for manipulating air-sensitive compounds. Microwave assisted reactions were performed in Anton-Par Monowave 300 microwave in Borosilicate glass standard vial G10. Toluene was distilled over CaH2 under an argon atmosphere. Tetrahydrofuran was distilled over sodium/benzophenone under an argon atmosphere. All other reagents and solvents were of commercial quality and used without further purification (substrates 1b, 2, 7, 9 and chiral phosphines). Analytical thin-layer chromatography (TLC) was performed on plates precoated with silica gel layers. The developed chromatogram was visualized by UV absorbance and/or vanillin stain. Flash column chromatography was performed using a GraceResolv[™] silica gel column on a Combi Flash® companion®. Nuclear magnetic resonance spectra (¹H, ¹³C, ³¹P) were recorded at 500 or 300 MHz spectrometers. Chemical shifts are reported in parts per million relative to an internal standard of residual chloroform (δ = 7.19 ppm for ¹H NMR and 77.16 ppm for ¹³C NMR). IR spectra were recorded on a Perkin-Elmer FT-IR spectrophotometer and are reported in reciprocal centimeters (cm⁻¹). High-resolution mass spectrometry (HRMS) was performed using electrospray ionization (ESI) and time-of-flight (TOF) analyzer, in positive-ion or negative-ion detection mode. HPLC was performed at a column temperature of 20°C on a Waters 2695 Separations Module equipped with a diode array UV detector. Data are reported as follows: column type, eluent, flow rate, retention time (t_r) . Substrates 1*H*-indole-7carbaldehyde 1c,^[26] 3-bromo-1*H*-indole-7-carbaldehyde 1d.^[26] methyl 1-formyl-9H-pyrido[3,4-b]indole-3carboxylate 1e, ^[27] tert-butyl (2-formylphenyl)carbamate 1f, [28] 4-methyl-N-(3-oxopropyl)benzenesulfonamide **4a**. (3-oxopropyl)carbamate ^[29]benzyl 4b.^[30] ethvl tosylglycinate **4c**,^[31] ethyl (benzyloxy)carbonyl)glycinate 4d,^[32] ethyl *L*-prolinate 4f,^[33] and P5,^[34] were prepared according to literature. Synthesis of 1g and 1-((2S,5R)-2isopropyl-5-methylcyclohexyl)phosphindole 1-oxide are described in the supporting information.

II. Experimental Procedures:

General procedure for the reaction in Schlenk Line.

In a Schlenk tube, amino-aldehydes or amino-esters (0.15 mmol, 1 equiv.), phospholene (5 mol %) *bis*(4-nitrophenyl)phosphate (5 mol %), and freshly distilled degassed toluene (0.15 M) were added. Dialkyl acetylene dicarboxylate (0.15 mmol, 1 equiv.) and phenylsilane (1 equiv.) were then added using microsyringes and the reaction mixture was heated at 60°C for the aldehyde derivatives and 120°C for the ester derivatives for 16 hours. The crude reaction mixture was concentrated and purified by flash chromatography using 4g GraceResolvTM silica gel pre-packed column and EtOAc/heptanes as eluent (0 to 40% of EtOAc over 25 min, 18 mL/min).

General procedure for the Microwave assisted reaction.

In a Standard Vial G10, amino-aldehydes or amino-esters (0.15 mmol, 1 equiv.), phospholene (5 mol %) bis(4nitrophenyl)phosphate (5 mol %), and freshly distilled degassed toluene (0.15 M) were added. Dialkyl acetylene dicarboxylate (0.15 mmol, 1 equiv.) and phenylsilane (1 equiv.) were then added using microsyringes. The vial was sealed by reusable snap-cap with PTFE coated silicone septum and the reaction mixture was then heated at 100°C for the aldehyde derivatives and 120°C for the ester derivatives for 2 hours. The crude reaction mixture was concentrated and purified by flash chromatography using 4g GraceResolvTM silica gel pre-packed column and EtOAc/heptanes as eluent (0 to 40% of EtOAc over 25 min, 18 mL/min).

7-bromo-9H-pyrrolo[1,2-a]indole-2,3-Diethyl dicarboxylate (3a)^[9] (52 mg, 92 % yield; Microwave: 53 mg, 93% yield). Yellow solid; mp 101-104°C; Rf 0.32 (20% EtOAc/heptanes); ¹H NMR (300 MHz, CDCl₃): $\delta =$ 7.91 (d, J = 8.5 Hz, 1H), 7.50-7.46 (1H, m), 7.39 (dd, J =8.5, 2.1 Hz, 1H), 6.44-6.41 (m, 1H), 4.35 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz, 2H), 3.79 (s, 2H), 1.33 (t, J = 7.1 Hz, 3H), 1.29 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 164.6$ (CO), 161.2 (CO), 139.8 (C), 138.6 (C), 137.1 (C), 130.8 (CH), 128.7 (CH), 125.4 (C), 119.0 (C), 118.2 (C), 116.2 (CH), 104.6 (CH), 61.5 (CH₂), 60.8 (CH₂), 28.9 (CH₂), 14.3 (CH₃), 14.1 (CH₃); IR: $v_{max} = 2980$, 1706, 1479, 1467, 1270, 1212, 1181, 1113, 1053, 751 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₇BrNO₄ [M+H]⁺: 378.0341, found: 378.0312.

Dimethyl 3*H***-pyrrolizine-5,6-dicarboxylate (3ba)** (29 mg, 90 % yield; Microwave: 30 mg, 91% yield). White solid; mp 63–65°C; R_f 0.41 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 6.55 (dt, *J* = 6.0, 2.1 Hz, 1H), 6.46 (dt, *J* = 6.0, 1.9 Hz, 1H), 6.35 (bs, 1H), 4.68-4.64 (m, 2H), 3.82 (s, 3H), 3.78 (s, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 164.9 (*C*O), 160.8 (*C*O), 143.6 (*C*), 132.6 (*C*H), 124.0 (*C*), 122.2 (*C*H), 120.4 (*C*), 102.3 (*C*H), 55.4 (*C*H₂), 51.8 (*C*H₃), 51.7 (*C*H₃); IR: v_{max} = 2997, 2952, 1730, 1693, 1486, 1447, 1317, 1290, 1252, 1206, 1184, 1151, 1138, 1079, 1055, 951, 777 cm⁻¹; HRMS (ESI) calcd. for C₁₁H₁₂NO₄ [M+H]⁺: 222.0766, found: 222.0760.

Diethyl 3*H***-pyrrolizine-5,6-dicarboxylate (3bb)** (31 mg, 83 % yield; Microwave: 36 mg, 85% yield). Yellow solid; mp 48–50 °C; R_f 0.39 (20% EtOAc/heptanes); ¹H NMR (300 MHz, CDCl₃): δ = 6.56 (dt, *J* = 6.0, 2.1 Hz, 1H), 6.46 (dt, *J* = 6.0, 1.9 Hz, 1H), 6.35 (bs, 1H), 4.68-4.64 (m, 2H), 4.34-4.21 (m, 4H), 1.33-1.26 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ = 164.7 (CO), 160.4 (CO), 143.5 (C), 132.4 (CH), 124.6 (C), 122.3 (CH), 120.3 (C), 101.9 (CH), 60.6 (CH₂), 55.3 (CH₂), 14.33 (CH₃), 14.30 (CH₃); IR: v_{max} = 2982, 1725, 1688, 1487, 1442, 1286, 1250, 1210, 1151, 1077, 1054, 766 cm⁻¹; HRMS (ESI) calcd. for C₁₃H₁₆NO₄ [M+H]⁺: 250.1079, found: 250.1066.

Di*tert***-butyl** *3H***-pyrrolizine-5,6-dicarboxylate** (**3bc**) (41 mg, 89% yield; Microwave: 41 mg, 89% yield). Orange oil; R_{*f*} 0.82 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): $\delta = 6.61$ (dt, J = 6.0, 2.1 Hz, 1H), 6.48 (dt, J = 6.0, 1.9 Hz, 1H), 6.31 (bs, 1H), 4.75-4.62 (m, 2H), 1.60 (s, 9H), 1.58 (s,

9H); ¹³C NMR (75 MHz, CDCl₃): δ = 163.7 (*C*O), 159.4 (*C*O), 142.7 (*C*), 131.9 (*C*H), 126.2 (*C*), 122.4 (*C*H), 121.7 (*C*), 101.4 (*C*H), 81.3 (*C*), 80.4 (*C*), 55.1 (*C*H₂), 28.4 (*C*H₃), 28.2 (*C*H₃); HRMS (ESI) calcd. for C₁₇H₂₃NNaO₄ [M+Na]⁺: 328.1525, found: 328.1522.

Diethyl 4*H*-pyrrolo[3,2,1-*ij*]quinoline-4,5-dicarboxylate (3c) (43 mg, 96 % yield; Microwave: 44 mg, 99% yield). Yellow solid; mp 93–95 °C; R_f 0.76 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 7.80 (d, *J* = 1.1 Hz, 1H), 7.48 (dd, *J* = 7.7, 1.0 Hz, 1H), 7.22 (d, *J* = 3.4 Hz, 1H), 7.07-6.91 (m, 2H), 6.47 (d, *J* = 3.0 Hz, 1H), 6.04 (s, 1H), 4.30-4.20 (m, 2H), 4.19-4.01 (m, 2H), 1.29 (t, *J* = 7.2 Hz, 3H), 1.17 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 168.3 (CO), 165.3 (CO), 134.6 (CH), 133.4 (C), 126.2 (CH), 125.1 (C), 124.3 (CH), 122.1 (C), 121.5 (CH), 120.9 (CH), 116.0 (C), 103.7 (CH), 62.1 (CH₂), 61.1 (CH₂), 58.4 (CH), 14.3 (CH₃), 14.0 (CH₃); IR: v_{max} = 2982, 2931, 1743, 1699, 1598, 1370, 1288, 1248, 1212, 1058, 1024, 1151, 794 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₈NO₄ [M+H]⁺: 300.1236, found: 300.1223.

Diethyl 1-bromo-4H-pyrrolo[3,2,1-ij]quinoline-4,5dicarboxylate (3d) (53 mg, 94 % yield; Microwave: 56 mg, 99% yield). Green solid; mp 67-70 °C; Rf 0.67 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 7.77 (d, J = 1.1 Hz, 1H), 7.40 (dd, J = 7.2, 1.5 Hz, 1H), 7.24 (s, 1H), 7.10-6.98 (m, 2H), 5.96 (bs, 1H), 4.24 (qd, J = 7.2, 1.1 Hz, 2H), 4.19-4.03 (m, 2H), 1.29 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 167.8 (CO), 165.0 (CO), 133.8 (CH), 132.8 (C), 125.1 (CH), 124.5 (C), 122.6 (CH), 122.4 (CH), 121.9 (C), 121.6 (CH), 116.2 (C), 92.7 (C), 62.3(CH₂), 61.4 (CH₂), 58.2 (CH), 14.2 (CH₃), 14.0 (CH₃); IR: v_{max} = 2982, 2931, 1743, 1602, 1598, 1368, 1289, 1244, 1214, 1179, 1069, 1023, 790, 742 cm⁻¹; HRMS (ESI) calcd. for C₁₇H₁₇BrNO₄ [M+H]⁺: 378.0341, found: 378.0342.

5,6-diethyl 2-methyl 6H-indolo[3,2,1-de][1,5] naphthyridine-2,5,6-tricarboxylate (3e) (53 mg, 86 % yield; Microwave: no reaction). Yellow-orange solid; mp 167-170 °C; Rf 0.17 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 8.67 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 7.9 Hz, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.57 (t, J = 7.6 Hz, 1H), 7.34 (t, J = 7.3 Hz, 1H), 6.27 (s, 1H), 4.37-4.23 (m, 2H), 4.03-4.15 (m, 2H), 3.99 (s, 3H), 1.32 (t, J = 7.3 Hz, 3H), 1.08 (t, J = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 166.7$ (CO), 166.3 (CO), 164.5 (CO), 141.0 (C), 139.4 (C), 135.9 (C), 135.6 (C), 135.2 (CH), 129.1 (CH), 128.4 (C), 125.9 (C), 122.8 (CH), 122.3 (C), 122.1 (CH), 119.8 (CH), 111.6 (CH), 62.5 (CH₂), 61.8 (CH₂), 57.3 (CH), 52.8 (CH₃), 14.1 (CH₃), 13.9 (CH₃); IR: v_{max} = 2982, 2949, 1740, 1707, 1635, 1435, 1373, 1269, 1248, 1223, 1192, 1165, 1116, 1020, 767, 750 cm⁻¹; HRMS (ESI) calcd. for C₂₂H₂₁N₂O₆ [M+H]⁺: 409.1400, found: 409.1389.

1-*tert*-**butyl- 2,3-diethyl quinoline-1,2,3(2***H***)-tricarboxylate** (**3f**) (41 mg, 73% yield (formation of a byproduct (10%)); Microwave: 39 mg, 70% yield). White solid; mp 131–134 °C; $R_f 0.76$ (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): $\delta = 7.81$ (bs, 1H), 7.57 (s, 1H), 7.39-7.33 (m, 1H), 7.30-7.26 (m, 2H), 7.13-7.08 (m, 1H), 6.31 (s, 1H), 4.42-4.29 (m, 2H), 4.15-3.99 (m, 2H), 1.58 (s, 9H) 1.39 (t, J = 7.0 Hz, 3H), 1.16 (t, J = 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 169.3$ (CO), 164.8 (CO), 152.4 (C), 136.7 (C), 134.1 (CH), 130.3 (CH), 128.6 (CH), 124.8 (C), 124.1 (CH), 123.8 (CH), 82.5 (C), 61.5 (CH₂), 61.1 (CH₂), 53.3 (CH), 28.2 (CH₃), 14.2 (CH₃), 13.9 (CH₃); IR: $v_{max} =$ 2980, 2936, 2908, 1744, 1710, 1368, 1290, 1247, 1230, 1202, 1156, 1128, 1025, 946, 856, 765 cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₅NNaO₆ [M+Na]⁺: 398.1580, found: 398.1573.

1-tosyl-1,2-dihydrobenzo[4,5]thieno[3,2-Diethyl b]pyridine-2,3-dicarboxylate (3g) (44 mg, 60% yield; Microwave: 44 mg, 60% yield). Yellow solid; mp 173-176 °C; Rf 0.67 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): $\delta = 8.32$ (dd, J = 8.5, 1.0 Hz, 1H), 7.69 (dd, J =7.9, 0.8 Hz, 1H), 7.48-7.31 (m, 2H), 7.19-7.13 (m, 2H), 7.02-6.89 (m, 3H), 6.05 (s, 1H), 4.26-4.09 (m, 2H), 4.03-3.85 (m, 2H), 2.27 (s, 3H), 1.25 (t, J = 7.2 Hz, 3H), 0.99 (t, J = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 167.8$ (CO), 163.7 (CO), 144.5 (C), 138.9 (C), 134.7 (C), 134.1 (C), 131.3 (C), 129.0 (CH), 128.1 (C), 127.2 (CH), 127.0 (CH), 126.5 (CH), 125.6 (CH), 125.3 (CH), 123.2 (C), 122.4 (CH), 62.1 (CH₂), 61.1 (CH₂), 57.4 (CH), 21.5 (CH₃), 14.3 (CH₃), 13.8 (CH₃); IR: v_{max} = 3068, 2982, 2940, 1739, 1703, 1608, 1500, 1365, 1292, 1258, 1236, 1185, 1170, 1145, 1089, 1020, 769, 731 cm⁻¹; HRMS (ESI) calcd. for C₂₄H₂₄NO₆S₂ [M+H]⁺: 486.1045, found: 486.1037.

1-tosyl-1,2,5,6-tetrahydropyridine-2,3-Diethyl dicarboxylate (5a) (45 mg, 79 % yield; Microwave: 46 mg, 81% yield). Colorless oil; $R_f 0.5$ (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): $\delta = 7.73$ (d, J = 8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 7.13-7.04 (m, 1H), 5.43 (s, 1H), 4.30-4.17 (m, 2H), 4.14-3.97 (m, 2H), 3.89 (dd, J = 14.0, 7.0 Hz, 1H), 3.30-3.19 (m, 1H), 2.42 (s, 3H), 2.39-2.28 (m, 1H), 2.26-2.14 (m, 1H), 1.29 (t, J = 7.3 Hz, 3H), 1.19 (t, J= 7.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 168.8 (CO), 164.5 (CO), 143.6 (C), 139.3 (CH), 137.1 (C), 129.5 (2CH), 127.2 (CH), 127.1 (C), 61.6 (CH₂), 61.0 (CH₂), 54.2 (CH), 38.5 (CH₂), 24.5 (CH₂), 21.5 (CH₃), 14.1 (CH₃), 13.9 (CH₃); IR: $v_{max} = 2982$, 2937, 2905, 1732, 1712, 1345, 1263, 1160, 1102, 1047, 1025, 996, 816, 716 cm⁻¹; HRMS (ESI) calcd. for C₁₈H₂₄NO₆S [M+H]⁺: 382.1324, found: 382.1319.

1-benzyl 2,3-diethyl 5,6-dihydropyridine-1,2,3(2H)tricarboxylate (5b) (49 mg, 90% yield; Microwave: 50 mg, 92% yield). Orange oil; Rf 0.53 (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃, rotamers): $\delta = 7.46-7.28$ (m, 5H), 7.12 (m, 1H), 5.63 (s, 0.4H), 5.52 (s, 0.6H), 5.34-5.08 (m, 2H), 4.37-4.08 (m, 5H), 3.23-2.92 (m, 1H), 2.52-2.18 (m, 2H), 1.36-1.14 (m, 6H); ¹³C NMR (75 MHz, CDCl₃, rotamers): δ=165.0 (CO), 139.1 (CH), 138.4 (CH), 136.4 (C), 128.5 (CH), 128.4 (CH), 128.1 (CH), 128.0 (CH), 127.7 (CH), 127.5 (C), 67.6 (CH₂), 67.5 (CH₂), 61.6 (CH₂), 60.9 (CH₂), 54.0 (CH), 53.8 (CH), 37.8(CH₂), 37.2 (CH₂), 25.2 (CH₂), 24.9 (CH₂), 14.1 (CH₃), 14.0 (CH₃); IR: $v_{max} = 2982, 2937,$ 2902, 1736, 1706, 1657, 1422, 1367, 1337, 1285, 1236, 1210, 1192, 1108, 1051, 1024, 762, 699 cm⁻¹; HRMS (ESI) calcd. for C₁₉H₂₄NO₆ [M+H]⁺: 362.1604, found: 362.1605.

10.1002/adsc.201700313

4-ethoxy-1-tosyl-2,5-dihydro-1H-pyrrole-2,3-Diethyl dicarboxylate (5c) (49 mg, 80 % yield; Microwave: 51 mg, 83 % yield). Yellow oil; $R_f 0.67$ (40% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 7.67 (d, J = 8.7 Hz, 2H), 7.27 (d, J = 8.7 Hz, 2H), 4.92 (dd, J = 4.5, 1.5 Hz, 1H), 4.41 (dd, J = 15.1, 4.5 Hz, 1H), 4.26 (dd, J = 15, 1.7 Hz, 1H), 4.16-3.95 (m, 6H), 2.37 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H), 1.17 (m, 6H); ¹³C NMR (75 MHz, CDCl₃): δ = 170.3 (CO), 163.3 (CO), 161.6 (CO), 144.3 (C), 134.1 (CO), 129.9 (CH), 127.5 (CH), 101.0 (C), 68.3 (CH₂), 65.1 (CH), 61.5 (CH₂), 60.2 (CH₂), 52.1 (CH₂), 21.5 (CH₃), 15.2 (CH₃), 14.1 (*C*H₃), 14.0 (*C*H₃); IR: v_{max} = 2984, 2943, 2908, 1741, 1644, 1369, 1333, 1211, 1163, 1090, 1027, 815, 764 cm⁻¹; HRMS (ESI) calcd. for C₁₉H₂₆NO₇S [M+H]⁺: 412.1430, found: 412.1425.

1-benzyl 2,3-diethyl 4-ethoxy-1H-pyrrole-1,2,3(2H,5H)tricarboxylate (5d) (54 mg, 92 % yield, Microwave: 57 mg, 97% yield). Light yellow solid; mp 95-98 °C; Rf 0.43 (40% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃, rotamers): $\delta = 7.37-7.20$ (m, 5H), 5.18-4.96 (m, 3H), 4.54-4.27 (m, 2H), 4.19-4.01 (m, 5H), 4.00-3.82 (m, 1H), 1.37-1.28 (m, 3H), 1.25-1.14 (m, 4H), 1.02 (t, J = 7.2 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃, rotamers): $\delta = 171.4$ (CO), 171.1 (CO), 164.1 (CO), 163.9 (CO), 161.9 (CO), 153.7 (C), 136.0 (C), 135.8 (C), 128.5 (CH), 128.4 (CH), 128.3 (CH), 128.2 (CH), 128.1 (CH), 128.0 (CH), 100.9 (C), 100.7 (C), 68.0 (CH₂), 67.6 (CH₂), 64.0 (CH), 63.6 (CH), 61.4 (CH₂), 61.2 (CH₂), 60.0 (CH₂), 50.9 (CH₂), 50.6 (CH₂), 15.2 (CH₃), 14.2 (CH₃), 14.1 (CH₃), 13.9 (CH₃); IR: v_{max} = 2983, 2934, 2908, 1737, 1717, 1640, 1410, 1354, 1240, 1212, 1113, 1059, 1028, 768 cm⁻¹; HRMS (ESI) calcd. for C₂₀H₂₆NO₇ [M+H]⁺: 392.1709, found: 392.1713.

5-benzyl-4-ethoxy-1H-(2*R*,5*S*)-1-benzvl 2,3-diethyl pyrrole-1,2,3(2H,5H)-tricarboxylate (5e) (40 mg, 55% yield). Yellow oil; $R_f 0.82$ (40% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃, rotamers): $\delta = 7.35-7.19$ (m, 5H), 7.18-7.01 (m, 4.2H), 5.24-4.99 (m, 2.8H), 4.76 (dd, J = 7.5, 3.8 Hz, 0.5H), 4.66-4.52 (m, 1.1H), 4.21-3.94 (m, 5.7H), 3.80 (q, J = 7.3 Hz, 1.1H), 3.36 (dd, J = 13.9, 4.1 Hz, 0.5H), 3.17 (dd, J = 13.6, 6.0 Hz, 0.5H), 3.04 (dd, J = 13.6, 6.8 Hz, 1.5H), 1.28-1.14 (m, 5.3H), 1.14-0.96 (m, 5H);¹³C NMR (75 MHz, CDCl₃, rotamers): $\delta = 171.0$ (CO), 170.8 (CO), 166.2 (CO), 165.4 (CO), 162.3 (CO), 154.2 (C), 153.6 (C), 137.8 (C), 137.6 (C), 136.2 (C), 135.9 (C), 129.7 (CH), 129.5 (CH), 128.4 (CH), 128.2 (CH), 128.0 (CH), 127.8 (CH), 126.4 (CH), 102.5 (C), 101.71 (C), 69.4 (CH₂), 69.2 (CH₂), 67.5 (CH2), 67.3 (CH2), 64.9 (CH), 64.7 (CH), 64.6 (CH), 64.0 (CH), 61.4 (CH₂), 61.3 (CH₂), 60.4 (CH₂), 41.3 (CH₂), 40.6 (CH_2) , 15.0 (CH_3) , 14.1 (CH_3) , 13.9 (CH_3) ; IR: $v_{max} = 2981$, 2934, 2905, 1739, 1711, 1634, 1407, 1345, 1270, 1213, 1109, 1062, 1027, 742, 700 cm⁻¹;HRMS (ESI) calcd. for C₂₇H₃₂NO₇ [M+H]⁺: 482.2179, found: 482.2199.

(2*S*,5*S*)-1-benzyl 2,3-diethyl 5-benzyl-4-ethoxy-1*H*pyrrole-1,2,3(2*H*,5*H*)-tricarboxylate (5e[•]) (20 mg, 27% yield). Yellow oil; R_f 0.75 (40% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃, rotamers): δ = 7.41-7.21 (m, 6.3H), 7.14-7.05 (m, 3.7H), 6.97-6.91 (m, 1.4H), 6.84-6.77 (m, 1H), 5.32-5.21 (m, 0.5H), 5.15-5.01 (m, 2H), 4.97-4.90 (m, 0.5H), 4.87-4.81 (m, 0.5H), 4.32-4.18 (m, 3.6H), 4.18-4.02 (m, 1.5H), 4.02-3.91 (m, 2.5H), 3.89-3.69 (m, 1.5H), 3.47 (dd, J = 13.8, 5.5 Hz, 0.5H), 3.17 (dd, J = 13.9, 5.3 Hz, 0.5H), 2.97-2.85 (m, 1.2H), 1.34-1.26 (m, 3.8H), 1.18 (t, J = 7.2Hz, 2H), 1.13-1.05 (m, 3.8H), 0.95 (t, J = 7.16 Hz, 2H); ¹³C NMR (75 MHz, CDCl₃, rotamers): $\delta = 171.4$ (CO), 171.1 (CO), 164.1 (CO), 164.0 (CO), 161.6 (CO), 153.6 (C), 153.2 (C), 136.0 (C), 135.9 (C), 135.3 (C), 135.1 (C), 129.8 (CH), 129.7 (CH), 128.6 (CH), 128.5 (CH), 128.4 (CH), 128.2 (CH), 128.2 (CH), 128.1 (CH), 127.9 (CH), 126.7 (CH), 126.1 (CH), 102.8 (C), 69.6 (CH₂), 69.3 (CH₂), 67.7 (CH₂), 67.2 (CH₂), 65.0 (CH), 64.6 (CH), 64.2 (CH), 63.8 (CH), 61.3 (CH₂), 61.1 (CH₂), 60.2 (CH₂), 36.8 (CH₂), 35.3 (CH₂), 15.4 (CH₃), 14.0 (CH₃), 13.8 (CH₃); IR: v_{max} = 2982, 2936, 2905, 1742, 1710, 1639, 1404, 1338, 1312, 1215, 1198, 1118, 1062, 1027, 768, 700 cm⁻¹; HRMS (ESI) calcd. for C₂₇H₃₂NO₇ [M+H]⁺: 482.2179, found: 482.2181.

(75)-diethyl 7-ethoxy-2,3,5,7a-tetrahydro-1*H*pyrrolizine-5,6-dicarboxylate (5f) (35 mg, 83% yield; Microwave: 36 mg, 84% yield). Yellow oil; $R_f 0.27$ (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): δ = 4.5 (s, 1H), 4.33-4.22 (m, 2H), 4.16-4.05 (m, 2H), 4.01 (dd, *J* = 14.0, 7.0 Hz, 2H), 3.42-3.33 (m, 1H), 3.29-3.17 (m, 1H), 2.22-2.11 (m, 1H), 2.05-1.88 (m, 3H), 1.27 (t, *J* = 7.2 Hz, 3H), 1.20 (t, *J* = 7.2 Hz, 3H), 1.15 (t, *J* = 7.1 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ = 171.8 (*C*), 167.3 (*CO*), 165.2 (*CO*), 151.4 (*C*), 86.8 (*C*H), 62.1 (*C*H₂), 61.4 (*C*H₂), 61.0 (*C*H), 59.3 (*C*H₂), 48.4 (*C*H₂), 30.5 (*C*H₂), 23.1 (*C*H₂), 14.4 (*C*H₃), 14.1 (*C*H₃), 13.8 (*C*H₃); IR: v_{max} = 2981, 2935, 2901, 1736, 1692, 1574, 1434, 1378, 1339, 1269, 1219, 1182, 1140, 1093, 1045, 1022, 792 cm⁻¹.

Synthesis of ylide 6.

In a round bottom flask, **4d** (50 mg, 0.21 mmol) and PPh₃ (55 mg, 0.21 mmol) were dissolved in DCM. **2a** (0.21 mmol, 34μ L) was added and the reaction was stirred overnight at room temperature. The crude reaction mixture was concentrated and purified by flash chromatography using 4g GraceResolvTM silica gel pre-packed column and EtOAc/heptanes as eluent (0 to 70% of EtOAc over 25 min, 18 mL/min) to obtain 141 mg (80 %) of the ylide **6** in two geometrical isomers as a yellow oil.

³¹P NMR (202 MHz, CDCl₃): δ = ppm 27.0, 26.0; HRMS (ESI) calcd. for C₃₈H₄₁NaO₈P [M+H]⁺: 670.2570 found: 670.2570.

General procedure for the synthesis of cyclopentan-2ene-1-one derivatives.

In a Schlenk tube, biacetyl or 1-phenylpropane-1,2-dione (0.6 mmol, 3 equiv.), phospholene (20 mol %) *bis*(4-nitrophenyl)phosphate (20 mol %), DIPEA (20 mol%), and freshly distilled degassed toluene (0.2 M) were added. Di*tert*-butyl acetylene dicarboxylate (0.2 mmol, 1 equiv.) and Me(EtO)₂SiH (2.8 equiv.) were then added using microsyringes and the reaction mixture was heated at 110 °C for 18 hours. The crude reaction mixture was concentrated and purified by flash chromatography using 4g GraceResolvTM silica gel pre-packed column and EtOAc/heptanes as eluent (30 to 40% of EtOAc over 25 min, 18 mL/min).

Di*tert***-butyl 3-methyl-4-oxocyclopent-2-ene-1,2dicarboxylate** (**8a**)^[24] (46 mg, 77% yield; Microwave: 39 mg, 65% yield). ¹H NMR (300 MHz, CDCl₃): δ = 3.82 (m, 1 H) 2.75 (dd, *J*=18.9, 7.9 Hz, 1 H) 2.48 (dd, *J*=18.9, 2.4 Hz, 1 H) 2.07 (d, *J*=2.4 Hz, 3 H) 1.56 (s, 9 H) 1.46 (s, 9 H)

Di-*tert*-**butyl 4-oxo-3-phenylcyclopent-2-ene-1,2dicarboxylate (8b)** (37 mg, 51 % yield; Microwave: 38 mg, 53% yield). Yellow oil; $R_f 0.76$ (30% EtOAc/PE); ¹H NMR (300 MHz, CDCl₃): $\delta = 7.34-7.29$ (m, 3H), 7.27-7.20 (m, 2H), 3.93 (dd, J = 7.6, 2.8 Hz, 1H), 2.82 (dd, J = 18.9, 7.9 Hz, 1H), 2.65 (dd, J = 18.9, 3.1 Hz, 1H), 1.41 (s, 9H), 1.28 (s, 9H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 205.2$ (CO), 170.4 (CO), 163.9 (CO), 155.8 (C), 146.2 (CO), 130.0 (CO), 129.1 (CH), 128.8 (CH), 127.8 (CH), 82.9 (C), 82.1 (C), 45.5 (CH), 38.8 (CH₂), 27.9 (CH₂), 27.7 (CH₂); IR: $v_{max} = 2979$, 2928, 1722, 1368, 1251, 1146, 844, 764, 697 cm⁻¹; HRMS (ESI) calcd. for C₂₁H₂₆NaO₅ [M+Na]⁺: 381.1678, found: 381.1680.

Acknowledgement

The authors acknowledge the support of the French "Agence Nationale de la Recherche" (ANR) for funding (grant number: ANR-13-JS07-0008) and the Centre National de la Recherche Scientifique (CNRS).

References

- [1] a) D. H. Valentine, J. H. Hillhouse, Synthesis 2003, 317-334; b) S. Xu, Z. He, RSC Adv. 2013, 3, 16885-16904.
- [2] C. G. Neochoritis, T. Zarganes-Tzitzikas, J. Stephanidou-Stephanatou, *Synthesis* **2014**, 537-585.
- [3] D. J. C. Constable, P. J. Dunn, J. D. Hayler, G. R. Humphrey, J. J. L. Leazer, R. J. Linderman, K. Lorenz, J. Manley, B. A. Pearlman, A. Wells, A. Zaks, T. Y. Zhang, *Green Chem.* **2007**, *9*, 411-420.
- [4] S. P. Marsden, A. E. McGonagle, B. McKeever-Abbas, Org. Lett. 2008, 10, 2589-2591.
- [5] J. An, R. M. Denton, T. H. Lambert, E. D. Nacsa, Org. Biomol. Chem. 2014, 12, 2993-3003.
- [6] For general reviews, see: a) A. Voituriez, N. Saleh *Tetrahedron Lett.* 2016, *57*, 4443-4451; b) H. A. van Kalkeren, F. L. van Delft, F. Rutjes, *ChemSusChem* 2013, *6*, 1615-1624; c) S. L. Xu, Y. H. Tang, *Lett. Org. Chem.* 2014, *11*, 524-533.
- [7] For some representative examples of phosphinecatalyzed reactions, see : Wittig reaction: a) C. J. O'Brien, J. L. Tellez, Z. S. Nixon, L. J. Kang, A. L. Carter, S. R. Kunkel, K. C. Przeworski, G. A. Chass, *Angew. Chem. Int. Ed.* **2009**, *48*, 6836-6839; b) C. J. O'Brien, Z. S. Nixon, A. J. Holohan, S. R. Kunkel, J. L. Tellez, B. J. Doonan, E. E. Coyle, F. Lavigne, L. J. Kang, K. C. Przeworski, *Chem. Eur. J.* **2013**, *19*, 15281-15289; c) C. J. O'Brien, F. Lavigne, E. E. Coyle,

A. J. Holohan, B. J. Doonan, Chem. Eur. J. 2013, 19, 5854-5858; d) E. E. Coyle, B. J. Doonan, A. J. Holohan, K. A. Walsh, F. Lavigne, E. H. Krenske, C. J. O'Brien, Angew. Chem. Int. Ed. 2014, 53, 12907-12911; e) M.-L. Schirmer, S. Adomeit, T. Werner, Org. Lett. 2015, 17, 3078-3081; f) H. A. van Kalkeren, C. te Grotenhuis, F. S. Haasjes, C. A. Hommersom, F. Rutjes, F. L. van Delft, Eur. J. Org. Chem. 2013, 7059-7066; g) L. Wang, Y. Wang, M. Chen, M.-W. Ding, Adv. Synth. Catal. 2014, 356, 1098-1104; Staudinger reaction: h) H. A. van Kalkeren, J. J. Bruins, F. P. J. T. Rutjes, F. L. van Delft, Adv. Synth. Catal. 2012, 354, 1417-1421; i) A. D. Kosal, E. E. Wilson, B. L. Ashfeld, Angew. Chem. Int. Ed. 2012, 51, 12036-12040; Appel reaction: j) H. A. van Kalkeren, S. H. A. M. Leenders, C. R. A. Hommersom, F. P. J. T. Rutjes, F. L. van Delft, Chem. *Eur. J.* **2011**, *17*, 11290-11295; Mitsunobu reaction: k) C. J. O'Brien (Univ. Texas, USA), US Patent 8901365, 2014; 1) J. A. Buonomo, C. C. Aldrich, Angew. Chem. Int. Ed. 2015, 54, 13041-13044; Miscellaneous : m) J. R. Harris, M. T. Haynes, II, A. M. Thomas, K. A. Woerpel, J. Org. Chem. 2010, 75, 5083-5091; n) W. Zhao, P. K. Yan, A. T. Radosevich, J. Am. Chem. Soc. 2015, 137, 616-619.

- [8] K. Fourmy, A. Voituriez, Org. Lett. 2015, 17, 1537-1540.
- [9] N. Saleh, A. Voituriez, J. Org. Chem. 2016, 81, 4371-4377.
- [10] a) I. Yavari, A. Ramazani, A. A. Esmaili J. Chem. Research (S) 1997, 208-209; b) I. Yavari, M. Adib, M. H. Sayahi, J. Chem. Soc. Perkin Trans 1 2002, 1517-1519; c) A. A. Esmaeili, H. Kheybari, J. Chem. Res., Synop. 2002, 9, 465-466; d) I. Yavari, H. Djahaniani, M. T. Maghsoodlou, N. J. Hazeri, Chem. Res., Synop. 1999, 382-383; e) I. Yavari, M. Adib, Tetrahedron 2001, 57, 5873-5878; f) M. Adib, M. H. Sayahi, Monatsh. Chem. 2006, 137, 207-211; g) G. C. Condie, J. Bergman, Eur. J. Org. Chem. 2004, 6, 1286-1297; h) L. A. Evans, K. E. Griffiths, H. Guthmann, P. Murphy, Tetrahedron Lett. 2002, 43, 299-301.
- [11] a) P. Martins, J. Jesus, S. Santos, L. R. Raposo, C. Roma-Rodrigues, P. V. Baptista, A. R. Fernandes, *Molecules* 2015, 20, 16852-16891; b) T. Shiro, T. Fukaya, M. Tobe, *Eur. J. Med. Chem.* 2015, 97, 397-408.
- [12] P. D. Bass, D. A. Gubler, T. C. Judd, R. M. Williams, *Chem. Rev.* 2013, 113, 6816.
- [13] J. M. Alvaro-Gracia, Rheumatology 2004 43, i21-i25
- [14] a) G. Z. Szilágyi, Z. N. Nagy, L. S. Balkay, I. N. Boros, M. S. Emri, S. Lehel, T. Z. Márián, T. S. Molnár, S. Szakáll, L. Trón, D. N. Bereczki, L. S. Csiba, I. N. Fekete, L. Kerényi, L. S. Galuska, J. Z. Varga, P. T. Bönöczk, Á. M. Vas, B. Z. Gulyás, *J. Neurol. Sci.* 2005, 229-230, 275–284; b) L. Dézsi, I. Kis-Varga, J. Nagy, Z. Komlódi, E. Kárpáti, *Acta Pharm Hung.* 2002, 72, 84– 91.

- [15] W. Cawello, A. Leonhardt, H. Schweer, H.W. Seyberth, R. Bonn, A.L. Lomeli, *Br J Clin Pharmacol.* 1995, 40, 273-276.
- [16] L. M. Harding, A. Adeniyi, R. Everson, S. Barker, D. J. Ralph, A. P. Baranowski, *Int J Impot Res* **2002**, *14*, 498-501.
- [17] M. Jouanneau, A. Tap, J. Ardisson, J.-P. Férézou, Synlett 2014, 25, 2171–2175.
- [18] T. Werner, M. Hoffaman, S. Deshmukh, Eur. J. Org. Chem. 2014, 6873-6876.
- [19] For the entrapment and identification of vinylphosphonium salts, see : S. Xu, R. Chen, A. He, J. Org. Chem. 2011, 76, 7528-7538.
- [20] S. M. H. Khorassani; M. T. Maghsoodlou; M. Nassiri; M. Zakarianezhad; M. Fattahi, ARKIVOC 2006, xvi, 168-184.
- [21] T. Werner, M. Hoffmann, S. Deshmukh, *Eur. J. Org. Chem.* 2014, 6630-6633. In this article, with phenylsilane as reducing agent, under microwave conditions at 150°C, the same product was obtained in 39% yield and 62% *ee*.
- [22] For reviews of asymmetric phosphine organocatalysis, see: a) A. Marinetti, A. Voituriez, Synlett 2010, 174; b) Z. Wang, X. Xu, O. Kwon, Chem. Soc. Rev. 2014, 43, 2927; c) W. Li, J. Zhang, Chem. Soc. Rev. 2016, 45, 1657; For selected examples of enantioselective phosphine-catalyzed umpolung aditions, see: d) J. Sun, G. C. Fu, J. Am. Chem. Soc. 2010, 132, 4568; e) Y. Fujiwara, G. C. Fu, J. Am. Chem. Soc. 2011, 133, 12293; f) S.Y. Lee, Y. Fujiwara, A. Nishiguch, M. Kalek, G. C. Fu, J. Am. Chem. Soc. 2015, 137, 4587; g) S. Kramer, G.C. Fu, J. Am. Chem. Soc. 2015, 137, 3803; h) T. Wang, Z. Yu, D. Hoon; C. Phee, Y. Lan, Y.-X. Lu, J. Am. Chem. Soc. 2016, 138, 265; and references cited therein.
- [23] C. E. Henry, Q. H. Xu, Y. C. Fan, T. J. Martin, L. Belding, T. Dudding, O. Kwon, J. Am. Chem. Soc. 2014, 136, 11890-11893.
- [24] I. Yavari, R. Amiri, M. Haghdadi, J. Chem. Res. 2004, 11, 766-767.
- [25] Y. Li, L.-Q. Lu, S. Das, S. Pisiewicz, K. Junge, M. Beller, J. Am. Chem. Soc. 2012, 134, 18325-18329.
- [26] M. Giardinetti, X. Moreau, V. Coeffard, C. Greck, *Adv. Synth. Catal.* 2015, 357, 3501-3506.
- [27] V. Singh, S. Hutait, S. Batra, Eur. J. Org. Chem. 2009, 6211-6216.
- [28] W. C. Gao, S. Jiang, R. L. Wang, C. Zhang, Chem. Comm. 2013, 49, 4890-4892.
- [29] S. R. Angle, D. S. Belanger, J. Org. Chem. 2004, 69, 4361-4368.
- [30] a) P. S. Chae, M-S. Kim, C-S. Jeung, S. D. Lee, H. Park, S. Lee, J. Suh, J. Am. Chem. Soc. 2005, 127, 2396-2397; b) L. Espelt, T. Parella, J. Bujons, C.

Solans, J. Joglar, A. Delgado, P. Clapés, *Chem. Eur. J.* **2003**, *9*, 4887-4899.

- [31] C. Olier, N. Azzi, G. Gil, S. Gastaldi, M. P. Bertrand, J. Org. Chem. 2008, 73, 8469-8473.
- [32] B. Seashore-Ludlow, P. Villo, P. Somfai, *Chem. Eur. J.* 2012, 18, 7219-7223.
- [33] G. Wang, N. Goyal, B. Hopkinson, *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3798-3803.
- [34] For a similar procedure, see: K. Yavari, S. Moussa, B.B. Hassine, P. Retailleau, A. Voituriez, A. Marinetti, *Angew. Chem. Int. Ed*, **2012**, *51*, 6748-6752.

FULL PAPER

Synthesis of Nitrogen-Containing Heterocycles and Cyclopentenone Derivatives via Phosphine-Catalyzed Michael Addition/Intramolecular Wittig Reaction

Adv. Synth. Catal. Year, Volume, Page - Page

Nidal Saleh, Florent Blanchard and Arnaud Voituriez*

